Open-label trial on efficacy and security of treatment with gemcitabine and oral modulation with tegafur and levofolinic acid (GEMTG) in patients with advanced pancreatic cancer.

Autor: Pericay Pijaume C; Oncology Department, Corporació Sanitària Parc Taulí, Sabadell, Barcelona, Spain. cpericay@gmail.com, Escudero Emperador P, Bastús Piulats R, Campos Cervera JM, Esquerdo Galiana G, Gallén Castillo M, Alfaro Gamero J, Dotor Navarro E, Pisa Gatell A, Guasch Jordán I, Saigí Grau E

Publikováno v: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico [Clin Transl Oncol] 2011 Jan; Vol. 13 (1), pp. 61-6.